Recombinant MLANA antibody
Quick Overview for Recombinant MLANA antibody (ABIN7477517)
Target
See all MLANA AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Immunogen
- Recombinant full-length hMART-1 protein
-
Isotype
- IgG
-
-
-
-
Application Notes
- IHC 1:50-1:100
-
Comment
-
Positive Control: Skin: Virtually all melanocytes should show a strong Melan A+ immunostaining including a weak to moderate staining in melanocytic dendrites. Adrenal gland: An at least moderate Melan A+ immunostaining should be seen in adrenocortical cells.
Negative Control: Kidney: Melan A immunostaining should be absent in all cells. Adrenal gland: Melan A+ immunostaining should be absent in all medullary cells.
-
Protocol
- Manual Protocol: Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121 °C in pH 7,8 Target Retrieval Solution buffer. Apply the antibody at a dilution of 1:75 at 37 °C for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer's directions.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Storage
- 4 °C,-20 °C,-80 °C
-
Storage Comment
- Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non- hazardous.
-
-
- MLANA (Melan A (MLANA))
-
Alternative Name
- Melan A
-
Background
- Antigen LB39-AA, Antigen SK29-AA, Melanoma antigen recognized by T-cells 1, MLAN-A, MLANA,Melan A antibody validated for immunohistochemistry on 76 different Normal Tissues
-
UniProt
- Q16655
Target
-